| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11060-012-0807-6 |
| P698 | PubMed publication ID | 22350376 |
| P2093 | author name string | Lauren E Abrey | |
| P2860 | cites work | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 |
| Cognitive functions in survivors of primary central nervous system lymphoma. | Q52002457 | ||
| Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. | Q52537604 | ||
| International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. | Q53158179 | ||
| Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. | Q55463931 | ||
| Longitudinal cognitive follow-up in low grade gliomas. | Q55467695 | ||
| Low-grade oligodendroglioma responds to chemotherapy. | Q55480129 | ||
| Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma | Q77302579 | ||
| Prediction of neurocognitive outcome in adult brain tumor patients | Q79896487 | ||
| Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study | Q28367133 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors | Q30426724 | ||
| Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab | Q30426728 | ||
| Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives | Q33194957 | ||
| Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...] | Q33247166 | ||
| Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy | Q33385596 | ||
| Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial | Q33395957 | ||
| Central nervous system effects of natural and synthetic glucocorticoids | Q33507425 | ||
| Neurocognitive function in brain tumors | Q33566768 | ||
| Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings | Q33621347 | ||
| Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. | Q33865523 | ||
| Getting the right dose of sex (chromosomes). | Q34480932 | ||
| Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases | Q34722872 | ||
| Phase II study of protracted daily temozolomide for low-grade gliomas in adults | Q34913346 | ||
| An update on cancer- and chemotherapy-related cognitive dysfunction: current status | Q35059702 | ||
| Mild cognitive impairment: conceptual issues and structural and functional brain correlates | Q35059777 | ||
| Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced ‘chemo-fog’ | Q35645883 | ||
| High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. | Q35800584 | ||
| Complications of radiation therapy on the brain and spinal cord | Q36002300 | ||
| CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. | Q36023980 | ||
| Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines | Q36729827 | ||
| The Impact of Chemo Brain on the Patient with a High-Grade Glioma | Q37782338 | ||
| Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. | Q40825914 | ||
| Neuropsychiatric disorders in cancer patients. | Q41103444 | ||
| Evidence for acute neurotoxicity after chemotherapy | Q42769499 | ||
| NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide | Q43245397 | ||
| Neurological outcome of long-term glioblastoma survivors. | Q43610731 | ||
| Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma | Q44411238 | ||
| Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy | Q44642100 | ||
| Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas | Q44663935 | ||
| Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. | Q45975080 | ||
| Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study | Q46433148 | ||
| Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. | Q46656239 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. | Q46771343 | ||
| Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings. | Q46782118 | ||
| Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial | Q46843406 | ||
| Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. | Q48493738 | ||
| Surviving glioblastoma for more than 5 years: the patient's perspective | Q48674676 | ||
| NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report | Q48874994 | ||
| P433 | issue | 2 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 285-290 | |
| P577 | publication date | 2012-02-17 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors | |
| P478 | volume | 108 |
| Q92446759 | Anaplastic astrocytoma and non-1p/19q co-deleted anaplastic oligoastrocytoma: long-term survival, employment, and performance status of survivors |
| Q48892586 | Effect of magnetic nanoparticle heating on cortical neuron viability |
| Q34036804 | Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma |
| Q48474040 | Long-term proper name anomia after removal of the uncinate fasciculus |
| Q48783178 | Low-grade gliomas and quality of life |
| Q30762118 | Management of low-grade gliomas: a review of patient-perceived quality of life and neurocognitive outcome |
| Q89656591 | Mitochondrial-associated impairments of temozolomide on neural stem/progenitor cells and hippocampal neurons |
| Q38131330 | Neurocognitive deficits following primary brain tumor treatment: systematic review of a decade of comparative studies |
| Q34094753 | Neurotoxicity of cancer chemotherapy |
| Q42840536 | Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery |
Search more.